These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. More from PHARMAC on long-acting insulin analogues: insulin glargine now funded. Moodie P N Z Med J; 2006 Jun; 119(1236):U2040. PubMed ID: 16807582 [No Abstract] [Full Text] [Related]
3. [Will prescribing all types of insulin no longer be allowed?]. Schmidt K MMW Fortschr Med; 2006 Mar; 148(10):44-6. PubMed ID: 16612950 [No Abstract] [Full Text] [Related]
5. [Comment on IOWiG report plan. A medical decision may not be replaced]. Vorstand der Deutschen Hochdruckliga E.V MMW Fortschr Med; 2006 May; 148(19):42. PubMed ID: 16736705 [No Abstract] [Full Text] [Related]
6. [The new drug cost saving package. Sensible measures or risk for patients?]. Krankenpfl J; 2002; 40(5-6):159. PubMed ID: 12271499 [No Abstract] [Full Text] [Related]
7. [Current cost analysis in the management of diabetes mellitus]. Oberender P Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S110-4; discussion S124-6. PubMed ID: 18686219 [TBL] [Abstract][Full Text] [Related]
8. [How many diabetic patients in your practice? Important references for regress defense]. MMW Fortschr Med; 2005 Oct; 147(40):48-9. PubMed ID: 16255517 [No Abstract] [Full Text] [Related]
9. PHARMAC responds on long-acting insulin analogues. Metcalfe S; Evans J; Moodie P N Z Med J; 2005 Oct; 118(1224):U1716. PubMed ID: 16258585 [No Abstract] [Full Text] [Related]
10. [Insulin therapy in type 2 diabetes. Insured patients would be willing to pay for added benefits]. MMW Fortschr Med; 2008 Dec; 150(49-50):56-7. PubMed ID: 19133372 [No Abstract] [Full Text] [Related]
11. [An experiment by the German health insurance demonstrates what disease management might entail. When big brother calls your patients.... ]. Schmidt K MMW Fortschr Med; 2002 Dec; 144(50):59-60. PubMed ID: 14610870 [No Abstract] [Full Text] [Related]
12. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Peterson GE Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343 [TBL] [Abstract][Full Text] [Related]
13. [Interview with the Daiichi-Sankyo managing director Ralf Göddertz (interview by Dirk Einecke and Cornelius Heyer)]. Göddertz R MMW Fortschr Med; 2013 Apr; 155(7):16. PubMed ID: 23668163 [No Abstract] [Full Text] [Related]
14. [Experiences with drug control in public health insurance medicine. Costs increase further and care becomes poorer]. MMW Fortschr Med; 2003 Jul; 145(29-30):57. PubMed ID: 12958782 [No Abstract] [Full Text] [Related]
15. [KBV faulted: there is not enough money for drugs. They have caused the deficit for physicians!]. MMW Fortschr Med; 2004 Aug; 146(33-34):46-7. PubMed ID: 15526627 [No Abstract] [Full Text] [Related]
16. [Biosimilars - Potential, risks and open questions]. Dtsch Med Wochenschr; 2014 Jan; 139(1-2):12-3. PubMed ID: 24551883 [No Abstract] [Full Text] [Related]
17. [Not just in the East: progressively shorter lengths of stay for patients. Clinics save, family physicians sigh]. Thomas A MMW Fortschr Med; 2006 Jan; 148(1-2):44-5. PubMed ID: 16610416 [No Abstract] [Full Text] [Related]
18. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)]. Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091 [TBL] [Abstract][Full Text] [Related]
19. [The German diabetes dilemma: DMP: insufficient management of the diabetic patient in general practice?]. MMW Fortschr Med; 2005 Oct; 147(41):10. PubMed ID: 16270503 [No Abstract] [Full Text] [Related]
20. [Clinical treatment pathways--1: High quality at low cost--an incompatible goal conflict?]. Küttner T; Wiese M; Roeder N Pflege Z; 2005 Mar; 58(3):176-9. PubMed ID: 15801701 [No Abstract] [Full Text] [Related] [Next] [New Search]